India reveals more toxic syrups months after poisoning deaths

by Rahul Devi

India’s drug regulator has found that cough syrup and an anti-allergy syrup manufactured by Norris Medicines are toxic, according to a government report. This revelation comes months after Indian-made cough syrups were linked to the deaths of 141 children worldwide. The contaminated medicines were found to contain diethylene glycol (DEG) or ethylene glycol (EG), the same contaminants found in the cough syrups responsible for the deaths in Gambia, Uzbekistan, and Cameroon since last year.

Officials from the Gujarat state’s Food and Drug Control Administration conducted an inspection of Norris’s factory last month and promptly ordered the suspension of production. Commissioner H.G. Koshia stated that the company “failed miserably on compliance parameters of good manufacturing practices.” He further noted that essential systems, such as an adequate water system and proper air-handling unit, were absent. In the interest of public health, the unit was ordered to halt production.

Despite attempts to reach out to Norris, the company did not respond to an email seeking comment. Additionally, the office numbers provided were not in service when contacted by Reuters. The Central Drugs Standard Control Organisation (CDSCO), the federal drug regulator, discovered that three batches of COLD OUT syrup manufactured by Fourrts (India) Laboratories were also contaminated with DEG and EG. This information was listed under “not of standard quality/spurious/adulterated/misbranded” drugs for August on the CDSCO website.

In August, the World Health Organisation (WHO) reported that a batch of COLD OUT sold in Iraq had unacceptable levels of DEG and EG. Fourrts Chairman S.V. Veeramani did not respond to requests for comments. Veeramani, who also serves as the chairman of the government-backed Pharmaceuticals Export Promotion Council of India, previously asserted in August that an “analysis of retention samples” of COLD OUT showed no contamination or toxins. He stated, “There is no report of any adverse effect or death due to the product.” As a precautionary measure, however, the company voluntarily recalled the product from the Iraqi market.

It is evident that the issue of contaminated cough syrup and anti-allergy syrup in India is an ongoing problem that poses significant risks to public health. The discovery of toxic substances in these medicines raises concerns about the country’s manufacturing practices and quality control systems. To better protect consumers, stricter regulations and more stringent quality assurance protocols need to be implemented across the pharmaceutical industry.

Disclaimer: This article has been auto-generated from a syndicated feed and has not been edited by the Devdiscourse staff.

You may also like